These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 24962276)

  • 1. AMPA receptor inhibitors for the treatment of neurological disorders.
    Niu L
    Future Med Chem; 2014 May; 6(8):849-952. PubMed ID: 24962276
    [No Abstract]   [Full Text] [Related]  

  • 2. Developing RNA aptamers for potential treatment of neurological diseases.
    Huang Z; Niu L
    Future Med Chem; 2019 Mar; 11(6):551-565. PubMed ID: 30912676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of cerebral infarct size by non-competitive AMPA antagonists in rats subjected to permanent and transient focal ischemia.
    Matucz E; Móricz K; Gigler G; Simó A; Barkóczy J; Lévay G; Hársing LG; Szénási G
    Brain Res; 2004 Sep; 1019(1-2):210-6. PubMed ID: 15306255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel AMPA receptor antagonists: synthesis and structure-activity relationships of 1-hydroxy-7-(1H-imidazol-1-yl)-6-nitro-2,3(1H,4H)- quinoxalinedione and related compounds.
    Ohmori J; Shimizu-Sasamata M; Okada M; Sakamoto S
    J Med Chem; 1996 Sep; 39(20):3971-9. PubMed ID: 8831762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The AMPA receptor as a therapeutic target: current perspectives and emerging possibilities.
    Mellor IR
    Future Med Chem; 2010 May; 2(5):877-91. PubMed ID: 21426207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4,5-Dihydro-1,2,4-triazolo[1,5-a]quinoxalin-4-ones: excitatory amino acid antagonists with combined glycine/NMDA and AMPA receptor affinity.
    Catarzi D; Colotta V; Varano F; Cecchi L; Filacchioni G; Galli A; Costagli C
    J Med Chem; 1999 Jul; 42(13):2478-84. PubMed ID: 10395489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute effects of AMPA-type glutamate receptor antagonists on intermale social behavior in two mouse lines bidirectionally selected for offensive aggression.
    Vekovischeva OY; Aitta-aho T; Verbitskaya E; Sandnabba K; Korpi ER
    Pharmacol Biochem Behav; 2007; 87(2):241-9. PubMed ID: 17537494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA aptamers for AMPA receptors.
    Huang Z; Niu L
    Neuropharmacology; 2021 Nov; 199():108761. PubMed ID: 34509496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negative allosteric modulation of wild-type and mutant AMPA receptors by GYKI 53655.
    Partin KM; Mayer ML
    Mol Pharmacol; 1996 Jan; 49(1):142-8. PubMed ID: 8569699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-Aminomethylquinoxaline-2,3-diones. Part I: A novel class of AMPA receptor antagonists.
    Auberson YP; Bischoff S; Moretti R; Schmutz M; Veenstra SJ
    Bioorg Med Chem Lett; 1998 Jan; 8(1):65-70. PubMed ID: 9871630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of GYKI 52466, a selective non-competitive antagonist of AMPA/kainate receptors, with conventional antiepileptic drugs in amygdala-kindled seizures in rats.
    Borowicz KK; Duda AM; Kleinrok Z; Czuczwar SJ
    Pol J Pharmacol; 2001; 53(2):101-8. PubMed ID: 11787948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dose-response study of neuroprotection using the AMPA antagonist NBQX in rat focal cerebral ischemia.
    Graham SH; Chen J; Lan JQ; Simon RP
    J Pharmacol Exp Ther; 1996 Jan; 276(1):1-4. PubMed ID: 8558416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Competitive AMPA receptor antagonists.
    Catarzi D; Colotta V; Varano F
    Med Res Rev; 2007 Mar; 27(2):239-78. PubMed ID: 16892196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Some central effects of GYKI 52466, a non-competitive AMPA receptor antagonist.
    Maj J; Rogóz Z; Skuza G; Kołodziejczyk K
    Pol J Pharmacol; 1995; 47(6):501-7. PubMed ID: 8868372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutamatergic mechanisms in different disease states: overview and therapeutical implications -- an introduction.
    Tzschentke TM
    Amino Acids; 2002; 23(1-3):147-52. PubMed ID: 12373529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of the antidyskinetic site of action of metabotropic and ionotropic glutamate receptor antagonists. Intracerebral infusions in 6-hydroxydopamine-lesioned rats with levodopa-induced dyskinesia.
    Maranis S; Stamatis D; Tsironis C; Konitsiotis S
    Eur J Pharmacol; 2012 May; 683(1-3):71-7. PubMed ID: 22410193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA aptamers selected against the GluR2 glutamate receptor channel.
    Huang Z; Pei W; Jayaseelan S; Shi H; Niu L
    Biochemistry; 2007 Nov; 46(44):12648-55. PubMed ID: 17929944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of novel quinoxaline-2,3-dione AMPA/GlyN receptor antagonists: amino acid derivatives.
    Nikam SS; Cordon JJ; Ortwine DF; Heimbach TH; Blackburn AC; Vartanian MG; Nelson CB; Schwarz RD; Boxer PA; Rafferty MF
    J Med Chem; 1999 Jun; 42(12):2266-71. PubMed ID: 10377233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Research on new AMPA antagonists of 2,3-benzodiazepine type.
    Sólyom S
    Pharmazie; 2001 Oct; 56 Suppl 1():S62-6. PubMed ID: 11686094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AMPA receptors as drug targets in neurological disease--advantages, caveats, and future outlook.
    Chang PK; Verbich D; McKinney RA
    Eur J Neurosci; 2012 Jun; 35(12):1908-16. PubMed ID: 22708602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.